5-(3-trifluoromethyl-phenyl)-pyrazolo[1,5-a]pyrimidine | 72851-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(3-trifluoromethyl-phenyl)-pyrazolo[1,5-a]pyrimidine
• 英文别名: 5-(α,α,α-Trifluoro-m-tolyl)pyrazolo[1,5-a]pyrimidine；5-(alpha,alpha,alpha-Trifluoro-m-tolyl)pyrazolo[1,5-a]pyrimidine；5-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidine
• CAS: 72851-87-7
• 化学式: C₁₃H₈F₃N₃
• 分子量: 263.222
• InChiKey: HTVHWCVZRGEQEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(3-trifluoromethyl-phenyl)-pyrazolo[1,5-a]pyrimidine 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium tetrahydroborate 、 N-溴代丁二酰亚胺(NBS) 、 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 3-(4-Methylsulfonylphenyl)-5-[3-(trifluoromethyl)phenyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure–Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines

  摘要：

  Toward improving pharmacokinetics, in vivo efficacy, and selectivity over hERG, structure activity relationship studies around the central core of antimalarial imidazo-pyridazines were conducted. This study led to the identification of potent pyrazolopyridines, which showed good in vivo efficacy and pharmacokinetics profiles. The lead compounds also proved to be very potent in the parasite liver and gametocyte stages, which makes them of high interest.

  DOI：

  10.1021/acs.jmedchem.5b01605
• 作为产物：
  描述：

  5-氯吡唑并[1,5-a]嘧啶 、 3-(三氟甲基)苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 5-(3-trifluoromethyl-phenyl)-pyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure–Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines

  摘要：

  Toward improving pharmacokinetics, in vivo efficacy, and selectivity over hERG, structure activity relationship studies around the central core of antimalarial imidazo-pyridazines were conducted. This study led to the identification of potent pyrazolopyridines, which showed good in vivo efficacy and pharmacokinetics profiles. The lead compounds also proved to be very potent in the parasite liver and gametocyte stages, which makes them of high interest.

  DOI：

  10.1021/acs.jmedchem.5b01605

文献信息

• [EN] TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES<br/>[FR] PROCEDE EN DEUX PHASES DESTINE A LA SYNTHESE DE PYRAZOLOPYRIMIDINES SELECTIONNES
  申请人：MALLINCKRODT INC

  公开号：WO2005070931A1

  公开（公告）日：2005-08-04

  An improved method of making a substituted pyrazolopyrimidine. The method comprises reacting a aminopyrazole compound or a salt thereof with a substituted 1-oxo-2-propenyl-arene(-heterocycle) or a salt thereof under acidic conditions in a reaction medium including a two-phase mixture of an aqueous solution and a water-immiscible organic liquid. Specific substituted pyrazolopyrimidines include N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide and N-methyl-N-(3-3-[2-thienylcarbonyl]-pyrazolo[1, 5-a]-pyrimidin-7-yl}phenyl)acetamide.

  一种改进的制备取代吡唑吡咯嘧啶的方法。该方法包括在酸性条件下，将氨基吡唑化合物或其盐与取代的1-氧代-2-丙烯基芳烃（-杂环）或其盐在包括水溶液和水不相溶有机液体的两相混合物中反应。特定的取代吡唑吡咯嘧啶包括N-[3-(3-氰基吡唑[1,5-a]嘧啶-7-基)苯基]-N-乙醋胺和N-甲基-N-(3-3-[2-噻吩甲酰]-吡唑[1,5-a]-嘧啶-7-基}苯基)乙醋胺。
• Imidazo[1,5-a]pyrimidines
  申请人：American Cyanamid Company

  公开号：US04236005A1

  公开（公告）日：1980-11-25

  This disclosure describes substituted pyrazolo[1,5-a]pyrimidines and imidazo[1,5-a]pyrimidines which possess anxiolytic activity.

  本文披露了具有抗焦虑活性的取代嘧唑并[1,5-a]嘧啶和咪唑并[1,5-a]嘧啶。
• Two-phase method for the synthesis of selected pyrazolopyrimidines
  申请人：Cantrell Lee Gary

  公开号：US20070155995A1

  公开（公告）日：2007-07-05

  An improved method of making a substituted pyrazolopyrimidine. The method comprises reacting a aminopyrazole compound or a salt thereof with a substituted 1-oxo-2-propenyl-arene(-heterocycle) or a salt thereof under acidic conditions in a reaction medium including a two-phase mixture of an aqueous solution and a water-immiscible organic liquid. Specific substituted pyrazolopyrimidines include N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide and N-methyl-N-(3-3-[2-thienyl-carbonyl]-pyrazolo[1,5-a]-pyrimidin-7-yl}phenyl)acetamide.

  一种改进的制备取代吡唑嘧啶的方法。该方法包括在酸性条件下，将氨基吡唑化合物或其盐与取代的1-氧代-2-丙烯基芳烃（杂环）或其盐在反应介质中反应，该反应介质包括水溶液和不溶于水的有机液体的两相混合物。具体的取代吡唑嘧啶包括N-[3-(3-氰基吡唑并[1,5-a]嘧啶-7-基)苯基]-N-乙酰胺和N-甲基-N-(3-3-[2-噻吩基-羰基]-吡唑并[1,5-a]-嘧啶-7-基}苯基)乙酰胺。
• ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES
  申请人：Gatti McArthur Silvia

  公开号：US20080300250A1

  公开（公告）日：2008-12-04

  The present invention relates to compounds of formula (I): wherein R 1 to R 3 , A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.

  本发明涉及式(I)的化合物： 其中R1至R3，A，M，L，E，G和J如描述和索赔中所定义。本发明还涉及制备这种化合物的方法，含有这些化合物的药物组合物以及治疗中枢神经系统疾病的方法。
• TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES
  申请人：MALLINCKRODT, INC.

  公开号：EP1713808A1

  公开（公告）日：2006-10-25